Il nostro standard di qualità: qualità lotto dopo lotto

Avextra è sinonimo di farmaci a base di cannabis di alta qualità. La nostra chiave del successo: la coltivazione in Portogallo e la combinazione di tradizione e alta tecnologia. Per saperne di più, guardate il video con il nostro CMO David Reckeweg-Lecompte.

Podcasts

Neil Smith è ospite da Planted con Sara Payan.

Sara Payan parla con Neil Smith, COO di Avextra, della situazione della cannabis in Europa e dei nuovi sviluppi della ricerca. Qui trovi l’intervista in inglese.

Comunicati stampa

Qui trovate gli ultimi comunicati stampa di Avextra.

Avextra und SynQube GmbH geben strategische Partnerschaft in der Arzneimittelentwicklung bekannt

Avextra und SynQube GmbH geben strategische Partnerschaft in der Arzneimittelentwicklung bekannt

Avextra und SynQube geben ihre strategische Partnerschaft bekannt. Beide Partner bündeln ihre umfangreiche Expertise im Bereich der Cannabistherapie für eine verbesserte Patientenversorgung in der GKV-Erstattung.

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines…

Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Bensheim, 23.01.2024 – Erste Studien zeigen, dass neuropathische Schmerzformen, wie CINP, eine vielversprechende Indikation für den Nutzen von CBMs darstellen könnten. Jedoch fehlt – wie…

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Bensheim, 18.10.2023 – Zum Deutschen Schmerzkongress in Mannheim kündigt Avextra seine Allianz für Evidenz mit dem Start von BELCANTO an: der ersten von Avextra unterstützten…

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Bensheim, 14.9.2022 – Der führende Anbieter von cannabisbasierten Arzneimitteln aus Deutschland mit neuem Namen: Aus Eurox wird Avextra…

Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra…

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Bensheim, 14.9.2022 – Der führende Anbieter von cannabisbasierten Arzneimitteln aus Deutschland mit neuem Namen: Aus Eurox wird Avextra…

Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.

Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.

Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra…

Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development

Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development

Avextra and SynQube jointly announce their strategic partnership. Both partners are combining their extensive expertise in the field of cannabinoid therapy to improve patient care…

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines…

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located…

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

Lisbon, January 17th, 2024 – Avextra, the leading German manufacturer of cannabis-based medicines, has entered a strategic, long-term partnership with the Instituto Universitário de Ciências…

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world…

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Bensheim, 14.9.2022 – Der führende Anbieter von cannabisbasierten Arzneimitteln aus Deutschland mit neuem Namen: Aus Eurox wird Avextra…

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Bensheim, 14.9.2022 – Der führende Anbieter von cannabisbasierten Arzneimitteln aus Deutschland mit neuem Namen: Aus Eurox wird Avextra…

Germany unveils scaled-down recreational cannabis legalization plan

Germany unveils scaled-down recreational cannabis legalization plan

Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra…

UFFICIO STaMPa

Lisa Schwede

Tel.: +49 30 408174037

E-Mail: press@avextra.com

IT